The intracellular bacterial pathogen Coxiella burnetii directs biogenesis of a parasitophorous vacuole (PV) that acquires host endolysosomal components. Formation of a PV that supports C. burnetii replication requires a Dot/Icm type 4B secretion system (T4BSS) that delivers bacterial effector proteins into the host cell cytosol. Thus, a subset of T4BSS effectors are presumed to direct PV biogenesis. Recently, the PV-localized effector protein CvpA was found to promote C. burnetii intracellular growth and PV expansion. We predict additional C. burnetii effectors localize to the PV membrane and regulate eukaryotic vesicle trafficking events that promote pathogen growth. To identify these vacuolar effector proteins, a list of predicted C. burnetii T4BSS substrates was compiled using bioinformatic criteria, such as the presence of eukaryote-like coiled-coil domains. Adenylate cyclase translocation assays revealed 13 proteins were secreted in a Dot/Icm-dependent fashion by C. burnetii during infection of human THP-1 macrophages. Four of the Dot/Icm substrates, termed Coxiella vacuolar protein B (CvpB), CvpC, CvpD, and CvpE, labeled the PV membrane and LAMP1-positive vesicles when ectopically expressed as fluorescently tagged fusion proteins. C. burnetii ⌬cvpB, ⌬cvpC, ⌬cvpD, and ⌬cvpE mutants exhibited significant defects in intracellular replication and PV formation. Genetic complementation of the ⌬cvpD and ⌬cvpE mutants rescued intracellular growth and PV generation, whereas the growth of C. burnetii ⌬cvpB and ⌬cvpC was rescued upon cohabitation with wild-type bacteria in a common PV. Collectively, these data indicate C. burnetii encodes multiple effector proteins that target the PV membrane and benefit pathogen replication in human macrophages.
C
oxiella burnetii is an intracellular pathogen and the etiological agent of human Q fever. This highly infectious Gram-negative bacterium is capable of colonizing mammalian, avian, and arthropod host organisms (1) . The pathogen is shed in high numbers by infected livestock and easily disseminated via aerosols (1) . C. burnetii exhibits a biphasic developmental cycle in which the bacterium transitions between small cell variant (SCV) and large cell variant (LCV) forms (2) (3) (4) . SCVs are 0.2 to 0.5 m in size with densely packed chromatin and low metabolic activity. Once internalized within a host cell, SCVs differentiate into replicative LCVs of ϳ1 m in size with dispersed chromatin. The compact structure of SCVs correlates with resistance to osmotic stress, sonic disruption, and high pressure (3, 5) . Therefore, the SCV is presumed to be the environmentally stable form of C. burnetii that facilitates disease transmission (3) .
Successful intracellular replication of C. burnetii in mononuclear phagocytes, such as alveolar macrophages, is required for development of human Q fever, a disease that typically manifests as an acute flu-like illness (6) . C. burnetii replicates within a specialized parasitophorous vacuole (PV) with characteristics of a phagolysosome (6) . After internalization by a host cell, C. burnetii is sequestered within a nascent phagosome that traffics canonically through the endolysosomal system to ultimately acquire late endosomal and lysosomal markers such as Rab7, lysosome-associated membrane protein 1 (LAMP1), and cathepsin D (7) . PV acquisition of acid hydrolases correlates with pronounced degradative activity that C. burnetii, by unknown mechanisms, is able to resist (7) . In response to vacuole acidification, C. burnetii becomes metabolically active, resulting in the synthesis of bacterial proteins required for PV maturation (8, 9) . PV biogenesis involves fusion of the vacuole with vesicles originating from endocytic, autophagic, and secretory pathways through processes regulated by multiple host factors, including Rab GTPases and soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) (10) (11) (12) (13) (14) (15) .
Translocation by C. burnetii of proteins directly into the host cell cytosol by a specialized type 4B secretion system (T4BSS) is required for PV formation (16) (17) (18) . The C. burnetii T4BSS is homologous to the virulence-associated T4BSS of Legionella pneumophila, encoded by defect in organelle trafficking (dot) and intracellular replication (icm) genes (19) . C. burnetii strains harboring Himar1 transposon (Tn) insertions in icmL or icmD (16, 17) , or deletions in dotA or dotB (20) , fail to secrete effector proteins and have severe defects in intracellular growth. Interestingly, a C. burnetii icmD::Tn mutant can replicate intracellularly if se-questered in a vacuole with wild-type C. burnetii that provide Dot/Icm functions in trans (16) . Collectively, these data confirm that Dot/Icm T4BSS function is essential for the productive infection by C. burnetii.
Based on similar function of L. pneumophila and C. burnetii Dot/Icm T4BSSs, investigators have extensively used L. pneumophila to screen candidate C. burnetii effectors for Dot/Icm-dependent secretion using either adenylate cyclase (CyaA) or ␤-lactamase (BlaM) translocation assays (17, 18, (21) (22) (23) (24) (25) . C. burnetii proteins are typically selected as candidate effectors using bioinformatic criteria that include the presence of eukaryote-like motifs (21, 23, 24) , a C terminus enriched in acidic residues (22, (25) (26) (27) , and/or a PmrA regulatory element upstream of the encoding gene promoter (21, 25, 28) . Screening of candidate effectors has resulted in the identification of approximately 130 C. burnetii proteins that are secreted in a Dot/Icm-dependent fashion (17, 18, (21) (22) (23) (24) (25) 29) . Recently, several groups have used new genetic tools to express proteins in C. burnetii and validate that substrates recognized by the L. pneumophila Dot/Icm system are also exported during C. burnetii infection of host cells, including six Dot/Icm substrates encoded by the QpH1 cryptic plasmid (18) and 21 substrates encoded by chromosomal genes (14, 17, 21, 25) .
C. burnetii Dot/Icm effectors are predicted to remodel host endomembrane compartments for generation of the replicationpermissive PV, but information is lacking on specific effector functions that promote this process. However, inactivation of C. burnetii genes is now possible, allowing direct assessment of effector requirements during C. burnetii infection of mammalian cells. From a Himar1 Tn mutant library, Weber et al. (25) identified 20 C. burnetii mutants where a Tn insertion disrupts a gene encoding a known T4BSS substrate. Five of these mutants exhibit impaired growth in J774A.1 mouse macrophages and, consequently, the affected genes are named cir genes for Coxiella effectors for intracellular replication. Martinez et al. (30) recently identified 12 C. burnetii Himar1 Tn mutants with significant growth defects in Vero epithelial cells where the Tn insertion disrupts a gene encoding a known Dot/Icm substrate. The functions of these Tn-disrupted effector-encoding genes are currently unknown (25, 30) .
Recently, we functionally characterized a new T4BSS effector protein, termed CvpA for Coxiella vacuolar protein A, that was identified based on the presence of a eukaryote-like leucine-rich repeat and multiple endocytic sorting motifs (14) . CvpA localizes to the PV membrane when ectopically expressed as a fusion to mCherry red fluorescent protein. A C. burnetii ⌬cvpA mutant displays severe defects in intracellular replication and PV biogenesis that are rescuable by genetic complementation. In uninfected cells, mCherry-CvpA labels the membrane of endocytic recycling vesicles, an interaction mediated by the multiple endocytic sorting motifs within CvpA that bind the heterotetrameric clathrin adaptor protein complex 2 (AP2) (14, 31) . Depletion of cellular AP2 or clathrin with small interfering RNA significantly inhibits C. burnetii replication. In addition, a mutated form of CvpA lacking endocytic motifs does not rescue growth of the ⌬cvpA mutant. Collectively, these data suggest CvpA modulates clathrin-mediated vesicle transport events on the PV membrane that promote vacuole biogenesis (14) . We predict additional C. burnetii effectors on the PV membrane regulate vesicle fusion events required for vacuole maturation and pathogen growth.
In the present study, bioinformatic criteria were used to com- 
MATERIALS AND METHODS
Bacterial and mammalian cell culture. C. burnetii Nine Mile RSA439 (phase II, clone 4) was cultivated axenically in ACCM-2 as previously described (32 Table  S1 in the supplemental material, and the primers used in plasmid construction are listed in Table S2 in the supplemental material. C. burnetii genes were amplified with Accuprime Pfx DNA polymerase (Invitrogen) from genomic DNA extracted from the Nine Mile (RSA439), Dugway (5J108-111), and K (Q154) strains of C. burnetii using gene-specific primers (Integrated DNA Technologies, Coralville, IA). For the construction of plasmids used in targeted deletion of C. burnetii genes, the 5= and 3= flanking sequences of cbu0021, cbu1556, cbu1818, and cbu1863 were PCR amplified using the respective primer pairs listed in Table S2 in the supplemental material. Using the In-Fusion PCR cloning system (BD Clontech, Mountain View, CA), the 5= and 3= amplicons were inserted into pJC-CAT linearized by BamHI/SalI digestion to generate pJC-CAT:: CBU0021-5=3=, pJC-CAT::CBU1556-5=3=, pJC-CAT::CBU1818-5=3=, and pJC-CAT::CBU1863-5=3=. The kanamycin cassette was amplified from pJB-Kan (32) using either P1169-Kan-NdeI-KO-F and P1169-Kan-NdeI-KO-R or P1169-Kan-AgeI-KO-F and P1169-Kan-AgeI-KO-R and then inserted into the NdeI or AgeI site located between the 5= and 3= sequences within the pJC-CAT constructs to produce pJC-CAT::CBU0021-5=3=-Kan, pJC-CAT::CBU1556-5=3=-Kan, pJC-CAT::CBU1818-5=3=-Kan, and pJC-CAT::CBU1863-5=3=-Kan, which were then used in targeted gene deletion (20) . For construction of Tn7 complementation plasmids, cbu1818 or cbu1863, and their upstream promoter regions were PCR amplified from genomic DNA by using the primer pairs CBU1818comp-F and CBU1818comp-R or CBU1863comp-F and CBU1863comp-R. PCR products were inserted into the EcoRI site of pMini-Tn7T-CAT (20) with In-Fusion to create pMini-Tn7T-CAT::CBU1818comp and pMini-Tn7T-CAT::CBU1863comp.
Genes conferring resistance to chloramphenicol, kanamycin, or ampicillin are approved for C. burnetii genetic transformation studies by the Rocky Mountain Laboratories Institutional Biosafety Committee and the Centers for Disease Control and Prevention, Division of Select Agents and Toxins Program.
C. burnetii transformation. Transformation and selection of C. burnetii ⌬cvp mutants was conducted as described previously (20) . Briefly, pJC-CAT::CBU0021-5=3=-Kan, pJC-CAT::CBU1556-5=3=-Kan, pJC-CAT::CBU1818-5=3=-Kan, and pJC-CAT::CBU1863-5=3=-Kan chromosomal integrants were selected by culturing the bacteria in ACCM-2 containing 350 g/ml kanamycin and 3 g/ml chloramphenicol and then subculturing the bacteria for 4 days in ACCM-2 supplemented with 1% sucrose and kanamycin to select for cointegrants that had excised the sacB-containing plasmid backbone. C. burnetii ⌬cvpB, ⌬cvpC, ⌬cvpD, and ⌬cvpE clones were isolated by limiting dilution in ACCM-2 and gene deletions confirmed by PCR (20) . Transformation and selection of C. burnetii ⌬cvp complement strains was accomplished as previously described (20) .
Construction of plasmids for expression of C. burnetii proteins in eukaryotic cells. C. burnetii effector-coding genes were amplified by PCR using the oligonucleotide primers listed in Table S2 in the supplemental material and cloned into pENTR/D-TOPO (Invitrogen). The plasmids were transformed into E. coli Top10 (Invitrogen), purified, and then cloned genes transferred to Gateway compatible pT-Rex-DEST30/NmCherry or pT-Rex-DEST30/N-GFP that allow anhydrotetracycline (aTet)-inducible expression of N-terminal mCherry or green fluorescent protein (GFP) fusion proteins. Plasmids were purified from E. coli TOP10 using the GenElute HP Plasmid Midiprep kit (Sigma, St. Louis, MO) and sequence confirmed.
Adenylate cyclase translocation assays. Adenylate cyclase assays were conducted as previously described (14) . Briefly, PMA-differentiated THP-1 macrophages were plated in 24-well plates (5 ϫ 10 5 cells/well) and infected at a multiplicity of infection (MOI) of 50 with C. burnetii strains expressing each of the candidate proteins N-terminally fused to CyaA. After a 48 h of incubation, the cells were washed with PBS and then lysed with 200 l of lysis buffer containing 50 mM HCl and 0.1% Triton X-100. Samples were boiled for 5 min, and 400 l of 95% ethanol was added. The samples were dried under vacuum and resuspended in 400 l of assay buffer (0.5 M sodium acetate [pH 6.0], 0.002% [wt/vol] bovine serum albumin). The amount of cyclic AMP (cAMP) in the samples was determined with the cAMP Biotrak enzyme immunoassay system (GE Healthcare, Piscataway, NJ) according to the nonacetylation procedure. Samples were measured in duplicate for each independent experiment (n ϭ 3). Values are reported as the fold change in cAMP concentration versus the empty vector control (CyaA only). Proteins were deemed T4BSS substrates if the fold change in cAMP concentration was significantly greater (P Ͼ 0.05) than the CyaA only control, as judged by one-way analysis of variance (ANOVA).
Ectopic expression and immunofluorescence microscopy. HeLa cells infected with C. burnetii for 24 h on 12-mm coverslips in a 24-well plate were transfected with 500 ng of the pT-REx-DEST30/N-GFP or pT-Rex-DEST30/N-mCherry constructs described above and 250 ng of pcDNA 6/TR (Invitrogen) using FuGENE HD (Promega, Madison, WI) as previously described (14) . The cells were incubated 24 h; fresh growth medium containing 1 g/ml aTc (Sigma) was then added to induce protein expression. The cells were fixed 24 h later with 4% paraformaldehyde and permeabilized with PBS containing 0.05% saponin and 5% FBS. For immunostaining, rabbit anti-LAMP1 polyclonal antibody (Abcam, Cambridge, England) and guinea pig anti-Coxiella serum (14) were used as primary antibodies, followed by goat anti-rabbit Alexa Fluor 594 (Invitrogen) and goat anti-guinea pig Alexa Fluor 647 (Invitrogen). Coverslips were mounted using Prolong Gold with DAPI (4=,6=-diamidino-2-phenylindole; Invitrogen) and imaged. For subcellular localization of ectopically expressed pT-Rex-DEST30/N-mCherry-CBU1556, cells were stained with a mouse antibody against transferrin receptor (Life Technologies) and goat anti-mouse Alexa Fluor 488 (Invitrogen). Imaging was conducted with a LSM710 confocal laser scanning microscope (Carl Zeiss Micro Imaging, Thornwood, NY) or a Nikon Eclipse Ti-E inverted microscope.
Quantification of C. burnetii growth and PV morphology. THP-1 cells seeded at 5 ϫ 10 5 per well in a 24-well plate were infected at an MOI of 0.5 with C. burnetii suspended in RPMI plus 10% FBS. Plates were centrifuged at 500 ϫ g for 20 min. Infected cells were washed once with PBS and then cultured in RPMI plus 10% FBS for the remainder of the experiment. For each of three independent experiments, samples were collected in duplicate on the day of infection (day 0) and 6 days postinfection. C. burnetii growth was assessed by quantifying genomic equivalents (GE) as previously described (14) .
To measure PV size, Vero cells (2 ϫ 10 4 ) on 12-mm coverslips in a 24-well plate were infected at an MOI of 5 with C. burnetii suspended in RPMI plus 2% FBS. Plates were centrifuged at 500 ϫ g for 20 min. Infected Vero cells were incubated 6 days and then fixed and stained with antibodies against LAMP1 and Coxiella as described above. Fluorescence micrographs were acquired, and 25 PV were measured for each C. burnetii strain in three independent experiments. For mutant complementation by coinfection, Vero cells (2 ϫ 10 4 ) on 12-mm coverslips in a 24-well plate were infected at MOIs of 5 and 2, respectively, with the ⌬cvp mutant and wildtype C. burnetii expressing mCherry red fluorescent protein (16) . The ⌬cvp mutants were visualized in PVs cohabited with wild-type C. burnetii at 6 days postinfection by immunostaining with antibodies against C. burnetii and LAMP1. Assessment of mutant PV fusion was conducted with Vero cells (2 ϫ 10 4 ) infected at an MOI of 100 with C. burnetii in RPMI plus 2% FBS. Cells were immunostained for LAMP1 and C. burnetii at 6 days postinfection, and the number of PVs in each cell (n ϭ 100) enumerated using fluorescence microscopy.
PV acidification. PV acidification was examined using LysoTracker Green DND-26 (Invitrogen) according to the manufacturer's protocol. Vero cells (2 ϫ 10 4 ) were infected at an MOI of 100 with C. burnetii in RPMI plus 2% FBS. Cells were incubated 6 days, treated with LysoTracker, and then immunostained for LAMP1 and C. burnetii.
Data analysis. GraphPad Prism 6.0 software (San Diego, CA) was used to perform one-way ANOVA or two-way ANOVA statistical tests. All image processing and measurements were conducted using ImageJ software (W. S. Rasband, National Institutes of Health, Bethesda, MD).
RESULTS

Identification of C. burnetii T4BSS effector proteins.
Bioinformatic analysis of the C. burnetii Nine Mile (RSA493), Dugway (5J108-111), and K (Q154) genomes (33) revealed 14 genes encoding predicted proteins with characteristics of T4BSS substrates ( Table 1 ). The identified candidate proteins contained eukaryotelike features, including coiled-coil and leucine-rich repeat domains associated with ligand recognition, and transmembrane domains predicted to mediate membrane attachment. CBU0885 contains a haloacid dehalogenase (HAD)-like domain associated with phosphatase activity (34), while CBU1457 harbors multiple Sel1 repeats known to promote protein-protein interactions (35) . In addition, several genes encoding candidate proteins contained PmrA regulatory elements (28) . Genes encoding each of the candidate effectors were inserted into pJB-CAT-CyaA, allowing C. burnetii expression of proteins N-terminally fused to the adenylate cyclase reporter protein CyaA (14, 18) . PMA-differentiated THP-1 human macrophages were infected with wild-type C. burnetii or ⌬dotA mutant strains expressing each of the CyaA constructs. THP-1 macrophages were also infected with wild-type C. burnetii transformed with the empty CyaA vector as a negative control. At 48 h postinfection, THP-1 cells were lysed, and the concentration of cytosolic cAMP measured (Fig. 1) . Expression of 13 CyaA fusion proteins by C. burnetii resulted in a significant fold increase in cAMP concentration relative to C. burnetii expressing CyaA alone. No increase in cAMP concentration was detected after infection with C. burnetii ⌬dotA expressing CyaA fusion proteins, indicating that secretion is Dot/Icm dependent. Collectively, these data indicated that CBU0021, CBU0534, CBU0885, CBUD0886, CBUK0790, CBU1493, CBUD0487, CBU1543, CBU1556, CBU1676, CBU1818, CBU1819, and CBU1863 are Dot/Icm substrates delivered to the host cell cytosol by the C. burnetii T4BSS. Negative translocation of CyaA-CBU1457 was not due to lack of expression since all CyaA fusion proteins were expressed as assessed by immunoblotting (data not shown).
C. burnetii effectors traffic to the PV. A subset of effector proteins within the repertoire of C. burnetii Dot/Icm substrates is predicted to localize to the PV membrane where they modify vesicle budding, transport, and fusion events to promote vacuole expansion. Indeed, CvpA was previously shown to localize to the PV membrane and contribute to PV biogenesis by a mechanism involving subversion of clathrin-mediated vesicular trafficking (14) . To identify additional PV-localized effector proteins, the 13 validated C. burnetii Dot/Icm substrates were ectopically expressed as N-terminal fusions to GFP or mCherry fluorescent protein in HeLa cells infected with C. burnetii. At 3 days postinfection, cells were fixed and stained with antibodies against LAMP1 and C. burnetii. The ectopically expressed Dot/Icm substrates displayed subcellular localizations ranging from diffuse cytoplasmic to punctate perinuclear ( Fig. 2A ; see also Fig. S1 in the supplemental material). Of the 13 proteins examined, CBU0021, CBU1556, CBU1818, and CBU1863 localized to the LAMP1-positive PV membrane ( Fig. 2A ; see also Fig. S1 in the supplemental material), suggesting they confer effector functions associated with PV biogenesis. Consequently, these proteins were termed CvpB, CvpC, CvpD, and CvpE, respectively. To examine whether Cvp effectors also interact with the PV early after infection, HeLa cells ectopically expressing the Cvp proteins were examined at 6 h postinfection. More than 90% of C. burnetii PV labeled with ectopically expressed CvpB, CvpC, CvpD, or CvpE, suggesting the effectors target vesicular components during the initial stages of PV maturation (see Fig. S2 in the supplemental material).
Although Cvp effectors traffic to the LAMP1-positive PV membrane, it remained possible that they also interact with membrane components outside the late endosomal compartment, as is the case with CvpA (14) . To further examine their subcellular itineraries, each Cvp protein was ectopically expressed N-terminally fused to GFP or mCherry red fluorescent protein in uninfected HeLa cells. Transfected cells were then stained with antibodies against protein markers of early, recycling, or late endosomes, the endoplasmic reticulum (ER), the ER-Golgi intermediate compartment (ERGIC), or the cis-Golgi or trans-Golgi. As expected, all of the Cvp effectors localized with late endosomal marker LAMP1 in uninfected cells. In addition, CvpC exhibited partial localization with transferrin receptor, a marker of recycling endosomes (Fig. 2B) . We have previously shown that ectopically expressed CvpA localizes to recycling endosomes and inhibits the uptake of transferrin (14) . However, ectopic expression of CvpC did not alter transferrin uptake (data not shown). Moreover, none of the Cvp proteins localized with structures that labeled with antibodies against EEA1 (early endosomes), calreticulin (ER), ERGIC53 (ERGIC), giantin (cis-Golgi), or p230/golgin-245 (trans-Golgi) (data not shown). Collectively, these results suggest CvpB, CvpC, CvpD, and CvpE are C. burnetii effectors that target components of the late endosomal system, and that CvpC also targets recycling endosomes. Cvp effectors promote intracellular replication and PV expansion. Localization to the PV membrane suggested CvpB, CvpC, CvpD, and CvpE promote PV biogenesis and C. burnetii intracellular replication. To assess this possibility, C. burnetii cvp deletion mutants were generated and growth was assessed in THP-1 macrophages by measuring the increase in GE over 6 days. Replication of the C. burnetii ⌬cvpB, ⌬cvpC, ⌬cvpD, and ⌬cvpE mutants was significantly impaired with 49-, 276-, 160-, and 110- fold increases in GE, respectively, relative to the 713-fold increase in GE observed for wild-type C. burnetii (Fig. 3A) . Defects in C. burnetii replication correlated with impaired PV biogenesis. All mutants occupied aberrantly small, tight-fitting vacuoles in Vero cells compared to the large and spacious PVs generated by wildtype C. burnetii (Fig. 3B) . PVs harboring C. burnetii ⌬cvpB, ⌬cvpD, and ⌬cvpE strains in Vero cells also exhibited impaired homotypic fusion with 57.5, 35.2, and 32.6%, respectively, containing two or more PVs compared to 16.2% of cells infected with wild-type C. burnetii (see Fig. S3A in the supplemental material) . Consistent with the presence of LAMP1, PVs containing ⌬cvp mutants were acidified, as evidenced by the accumulation of the acidotropic fluorescent dye LysoTracker DND-26 (see Fig. S3B in the supplemental material). These acidified vacuoles supported metabolic activation of ⌬cvp mutants as each was capable of secreting a CyaA-CvpA fusion protein (14) (see Fig. S4 in the supplemental material). Thus, ⌬cvp mutant growth defects likely result from inactivation of the targeted effector.
To confirm that the specific gene deletion was responsible for the intracellular growth defect of a ⌬cvp mutant, complementation was attempted using Tn7 to introduce a single gene copy into the chromosome under the control of a native promoter. Tn7 complementation rescued intracellular growth of the ⌬cvpD and ⌬cvpE mutants, as evidenced by significant increases in replication within THP-1 cells (Fig. 4A) and PV size in Vero cells (Fig. 4B) . This strategy of genetic complementation failed to rescue impaired growth of C. burnetii ⌬cvpB and ⌬cvpC. Transformation with a multicopy plasmid encoding constitutively expressed CvpB and CvpC also failed to complement mutant growth defects (data not shown). Therefore, we used a coinfection strategy that has been previously used to show that the growth deficiencies of C. burnetii Dot/Icm mutants can be complemented by functions provided in trans by wild-type C. burnetii (16, 25) . Vero cells were coinfected with wild-type C. burnetii and the ⌬cvpB or ⌬cvpC strain. When sequestered within a PV co-occupied by wild-type C. burnetii, the ⌬cvpB and ⌬cvpC mutants exhibited robust replication (Fig. 5) .
DISCUSSION
The pronounced fusogenicity of the C. burnetii PV is predicted to be mediated by C. burnetii Dot/Icm effector proteins that modulate vesicle budding, transport, and fusion events on the PV membrane (6, 9, 14, 36) . In support of this model is CvpA, a PVinteracting Dot/Icm effector protein that promotes PV formation (14) . CvpA targets clathrin-dependent vesicular trafficking, presumably allowing C. burnetii to acquire membrane components for PV biogenesis (14) . In the present study, we used genetic manipulation of C. burnetii to directly identify Dot/Icm T4BSS substrates secreted by the pathogen and to validate their importance in intracellular replication. Based on interactions with the PV membrane, four new Cvp proteins were identified among the 13 identified Dot/Icm substrates. Defects in intracellular replication and PV expansion observed for C. burnetii ⌬cvp mutants support the hypothesis that C. burnetii encodes a family of Dot/Icm effectors that localize to the PV membrane and modulate membrane trafficking events necessary for PV development and pathogen replication.
The ⌬cvp mutants occupy a LAMP1-positive, acidified PV and can secrete proteins via the T4BSS. Thus, their growth deficiencies are not related to overall failings in PV maturation and Dot/Icm function. The ⌬cvpB, ⌬cvpD, and ⌬cvpE mutants, but not the ⌬cvpC mutant, generated multi-PV in Vero cells that displayed impaired homotypic fusion. These phenotypes correlated with a severe replication defect. Rescue of mutant growth defects by Tn7 cis-complementation verified mutation of CvpD and CvpE impairs C. burnetii intracellular growth, but this strategy failed to complement growth of the ⌬cvpB and ⌬cvpC mutants. The reasons for lack of genetic complementation remain unclear, but may include temporal problems with gene expression, insufficient chaperone engagement, and/or altered protein levels. To bypass these issues, we and others have used coinfection with wild-type C. burnetii to rescue impaired growth of strains with mutations in the T4BSS apparatus (16, 30) and Dot/Icm effectors (25) . Although coinfection rescued the growth defects of ⌬cvpB and ⌬cvpC mutants, we cannot rule out the possibility that the phenotypes are due to a secondary mutation that can also be complemented in trans.
The observation that cvpB, cvpC, cvpD, and cvpE are maintained as full-length genes among sequenced C. burnetii strains suggests that they modulate core host cell functions required for successful intracellular parasitism by the genus Coxiella. Polymorphisms among several previously identified C. burnetii Dot/Icm substrates (17, 24) are hypothesized to contribute to pathogenic potential (36) . Of the substrates identified in the present study, cbud0487 is full length only in the Dugway (5J108-111) strain, cbud0886 is full length only in the Dugway (5J108-111) and K (Q154) strains, and cubk0790 is only full length only in the K (Q154) strain. The Nine Mile strain used here is representative of acute disease isolates, the K strain is a human chronic endocarditis isolate, and the Dugway strain is an attenuated rodent isolate (33) .
Localization of bacterial effector proteins to pathogen-occupied vacuoles is commonly observed. For example, L. pneumophila translocates multiple effector proteins via its Dot/Icm T4BSS that interact with the membrane of the Legionella vacuole (LV). Dot/Icm effectors LidA, SidC, and DrrA/SidM bind specific phosphoinositides (37, 38) , while LepA, LepB, LegC3, LegC2/YlfB, and LegC7/YlfA contain transmembrane domains that facilitate inter- action with the LV membrane (39, 40) . Similarly, Chlamydia spp. deploy a type 3 secretion system (T3SS) to deliver multiple Inc family proteins that localize to the chlamydial inclusion via a conserved bilobed hydrophobic motif (41) . CvpC, CvpD, and CvpE all contain predicted transmembrane domains that may facilitate their interaction with the LAMP1-positive PV membrane. In contrast, CvpB lacks obvious transmembrane domains and therefore might target the PV membrane by binding phosphoinositides. When examined in uninfected cells, CvpB, CvpD, and CvpE consistently localize only to the late endolysosomal compartment. CvpC, in addition to LAMP1-positive structures, also localizes with transferrin receptor, an endocytic carrier protein that undergoes clathrin-dependent endocytosis and traffics through the endocytic recycling system. Thus, CvpC may traffic between late and recycling endosomal compartments, as is the case with CvpA (14) .
The activities of vesicular effectors produced by other pathogens may provide clues to Cvp biochemical activities. Modulation of Rab GTPases is a prominent strategy used by intracellular pathogens to remodel their phagosome into a replication-permissive compartment (42, 43) . Rab GTPases play critical roles in regulating transport of lipids and proteins that ultimately determine organelle identity (44, 45) . Guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) regulate the rate of cycling between inactive GDP-bound and active GTP-bound forms of Rab GTPases (45) . Pathogens secrete effectors that subvert these regulatory mechanisms to control spatial and temporal aspects of membrane transport. Of the LV-localized Dot/Icm effectors produced by L. pneumophila, multiple proteins modulate Rab1 activity to refurbish the LV with ER components and to prevent LV fusion with lysosomes. For example, LidA binds Rab1, which stabilizes its activation (46) and promotes the acquisition of ER-derived vesicles (47) . Furthermore, DrrA/SidM is a GEF that posttranslationally modifies Rab1 with AMP (48-51), thereby preventing inactivation by GAP proteins (52) (53) (54) . Rab1 (12) , as well as the regulators of endocytic traffic Rab5 and Rab7, have been implicated in C. burnetii PV biogenesis (15, 55, 56) . Thus, it is plausible that C. burnetii Cvp effectors disregulate Rab GTPases to promote maturation of its strikingly large phagolysosome-like replication compartment.
The Cvp effectors lack homology to proteins of known function, but CvpB, CvpC, and CvpD contain predicted eukaryotelike coiled-coil domains similar to bacterial effectors known to functionally mimic the activity of eukaryotic SNARE proteins (57) . SNAREs regulate fusion between transport vesicles and target compartment membranes, and pathogens subvert SNARE function to promote fusion events beneficial to pathogen growth (57) . The chlamydial T3SS substrate IncA harbors two SNARElike coiled-coil motifs (58) and inhibits membrane fusion mediated by endocytic, but not exocytic, SNARE complexes (59) . Expression of the L. pneumophila effector LegC3 produces a vacuolar protein sorting defect in yeast (40) linked to the disruption of trans-SNARE complexes by coiled-coil domains within the effector (60) . In contrast to L. pneumophila and Chlamydia spp. that block fusion of their vacuoles with lysosomes, phagosome acidification and lysosomal fusion promotes Coxiella replication (6) . Moreover, C. burnetii also requires membrane components from autophagic and secretory compartments for PV expansion (10-12, 15, 61) . Several SNARE proteins, including syntaxin-8, syntaxin-17, and vesicle-associated membrane protein 7 (VAMP7), localize to the PV membrane, with syntaxin-17 and VAMP7 having demonstrated roles in vacuole expansion (11, 15) . Coxiella researchers are just beginning to investigate the molecular mechanisms that control PV fusogenicity, a process that likely involves the activities of multiple Rab GTPases, SNARE proteins, and Dot/ Icm effectors (11, (14) (15) (16) .
When this manuscript was originally submitted, 4 of the 13 proteins we report here as substrates of the C. burnetii Dot/Icm system had also been described as L. pneumophila Dot/Icm substrates (21, 22, 25) . Using a hidden semi-Markov model, Lifshitz et al. (22) identified a group of C. burnetii proteins, termed C-terminal signal for effector translocation of C. burnetii (CetCb) proteins, that have C-terminal amino acid sequences resembling those of known Dot/Icm substrates. In agreement with our findings using C. burnetii, CvpB/CetCb1 (CBU0021) and CetCb4 (CBU0885) fusions with CyaA are translocated by L. pneumophila in a Dot/Icm-dependent manner (22) . Chen et al. (21) expressed multiple C. burnetii proteins in L. pneumophila fused to the ␤-lactamase (BlaM) reporter. These researchers concluded that CBU1457, CBU1543, and CvpC (CBU1556) are Dot/Icm substrates based on 2, 25, and 50% translocation efficiencies of the respective BlaM fusion protein (21, 25) . We found that CBU1543 and CvpC fusions with CyaA are translocated by C. burnetii in a Dot/Icm-dependent fashion. In contrast, we did not detect translocation of CyaA-CBU1457 by C. burnetii at the 48-h postinfection time point. Translocation was also not detected at 72 or 96 h postinfection, nor with L. pneumophila using standard assay conditions (data not shown) (18) . The reason for this disparate result is unclear but emphasizes the need to validate Dot/Icm effectors directly in C. burnetii.
Since submission of the manuscript, a study by Lifshitz and coworkers (62) demonstrated L. pneumophila Dot/Icm-dependent secretion of CBU1676 and CBU1818 (CvpD). Expression of CBU1676, or its paralog CBU0885, inhibits mitogen-activated protein kinase signaling in Saccharomyces cerevisiae. Newton et al. (63) reported that C. burnetii cig2 (cvpB) Tn insertion mutants exhibit a multi-PV growth phenotype in HeLa cells without showing an overall growth defect. We found that C. burnetii ⌬cvpB replicates poorly in THP-1 human macrophages, a behavior that correlates with generation of multiple, small PVs in Vero cells. Martinez et al. (30) also found that C. burnetii strains harboring a Tn insertion in cbu0021 (cvpB) display impaired growth in Vero cells. Thus, accumulating evidence from independent laboratories indicates CvpB is a critical Dot/Icm effector that subverts cellular functions involved in PV biogenesis. Indeed, because PVs containing the cvpB mutant do not accumulate the autophagosome protein LC3, and autophagy inhibition of cells infected with wildtype bacteria produce multiple PVs similar to the C. burnetii cvpB mutant, Newton et al. (63) conclude that CvpB promotes PV interactions with autophagosomes that enhance PV maturation. Biochemical characterization of the functional activities CvpB and other Cvp effectors will provide important insight into mechanisms governing PV development. 
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